CytoDel® Inc. was founded in 2012 to commercialize technology developed by its founders in the labs of Dr. Konstantin Ichtchenko at New York University School of Medicine (NYU). The Company’s patented and proprietary technology enables recombinant derivatives of botulinum neurotoxin (BoNT) to be engineered to create high value products with customized properties, and to deliver active agents to therapeutic targets inside neurons. BoNT is best known as the active ingredient in pharmaceutical products such as Botox® (Allergan).

The ongoing development of each program is synergistic and a regulatory pathway via the Animal Rule for Biodefense can lead to an approval and potential revenue as early as 2023. This is a non-traditional route through a special group at the FDA. CytoDel's technology allows for the manipulation of BoNT at the molecular level, to create engineered “Botox-like” products with tailored pharmaceutical properties such as larger therapeutic window and longer duration of action. The engineered BoNT can be used as a “Trojan horse” to deliver therapeutic antibodies inside of neurons with the lead program utilizing this technology in the development of antidotes for Botulism intoxication.

For more information on our science click on the TECHNOLOGY tab above.